

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE**  
**STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

**COMPLETE IF KNOWN**

|                               |                  |
|-------------------------------|------------------|
| <b>Application Number</b>     | 10/554,001       |
| <b>Filing Date</b>            | October 21, 2005 |
| <b>First Named Inventor</b>   | Mark T. Bilodeau |
| <b>Group Art Unit</b>         | To be determined |
| <b>Examiner Name</b>          | To be determined |
| <b>Attorney Docket Number</b> | 21299YP          |

Sheet 2 of 2

### NON PATENT LITERATURE DOCUMENTS

[illegible]

/CC/

Cite  
No.

**Bilodeau, et al. Database on Stn. No. 139:350754, WO 2003/086394**

Barnett, et al. Database on Stn. No. 139:323527, WO 2003/084473 ~~(2003)~~ (2003)

Zhao, et al. *Biorganic & Medicinal Chemistry Letters*, Vol. 15 (4), pp. 905-909, Database o Sin. No. 142:211437 (2005)

DeFeo-Jones, et al. *Molecular Cancer Therapeutics*, Vol. 4(2), pg. 271-279 (2005)

/CC/

**Lindsley, et al. Bioorganic & Medicinal Chemistry Letters, Vol. 15(3), pg. 761-764 (2005)**

**Examiner  
Signature**

/Celia Chang/

**Date Considered**

7/11/2008

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form \* IDS Form\* (IDS Folder), Merck & Co., Inc., -7/12/2005